The document provides guidelines from the ADA in 2013 on hypertension and blood pressure control for patients with diabetes. It recommends screening blood pressure at every visit and confirming elevated readings on a separate day. For those over 120/80 mmHg, lifestyle changes are advised, and for those over 140/80 mmHg, pharmacological therapy should be promptly initiated to achieve targets. An ACE inhibitor or ARB is recommended as part of a multiple drug regimen, with monitoring of kidney function and potassium levels.
I. Introduction
A. Brief explanation of World Hypertension Day
B. Importance of addressing hypertension as a global health issue
C. Overview of the objectives of the presentation
II. Understanding Hypertension
A. Definition and classification of hypertension
B. Prevalence and global burden of hypertension
C. Risk factors and causes of hypertension
D. Health implications and complications associated with hypertension
III. World Hypertension Day 2023
A. Background and significance of World Hypertension Day
B. Theme and key messages for World Hypertension Day 2023
C. Activities and events organized worldwide to raise awareness
IV. Goals and Objectives
A. Key goals set for World Hypertension Day 2023
B. Promoting prevention and early detection of hypertension
C. Encouraging healthy lifestyle modifications
D. Enhancing public knowledge about hypertension management
V. Initiatives and Campaigns
A. Overview of global initiatives and campaigns
B. Collaborations with international organizations, NGOs, and healthcare professionals
C. Campaign materials and resources available for public use
VI. Strategies for Hypertension Prevention and Control
A. Implementing population-level interventions
B. Screening and diagnosis strategies
C. Lifestyle modifications (diet, physical activity, stress management)
D. Pharmacological management and treatment guidelines
VII. Public Awareness and Education
A. Importance of raising public awareness about hypertension
B. Educational campaigns and resources for the general public
C. Role of healthcare professionals in educating patients
VIII. Impact and Achievements
A. Highlighting the impact of previous World Hypertension Day campaigns
B. Success stories and achievements in hypertension prevention and control
C. Lessons learned and areas for improvement
IX. Conclusion
A. Recap of the key points discussed
B. Call to action for individuals, communities, and policymakers
C. Encouragement to spread awareness and take steps towards hypertension prevention
Dr. Sachin Verma is a young, diligent and dynamic physician. He did his graduation from IGMC Shimla and MD in Internal Medicine from GSVM Medical College Kanpur. Then he did his Fellowship in Intensive Care Medicine (FICM) from Apollo Hospital Delhi. He has done fellowship in infectious diseases by Infectious Disease Society of America (IDSA). He has also done FCCS course and is certified Advance Cardiac Life support (ACLS) and Basic Life Support (BLS) provider by American Heart Association. He has also done a course in Cardiology by American College of Cardiology and a course in Diabetology by International Diabetes Centre. He specializes in the management of Infections, Multiorgan Dysfunctions and Critically ill patients and has many publications and presentations in various national conferences under his belt. He is currently working in NABH Approved Ivy super-specialty Hospital Mohali as Consultant Intensivists and Physician.
I. Introduction
A. Brief explanation of World Hypertension Day
B. Importance of addressing hypertension as a global health issue
C. Overview of the objectives of the presentation
II. Understanding Hypertension
A. Definition and classification of hypertension
B. Prevalence and global burden of hypertension
C. Risk factors and causes of hypertension
D. Health implications and complications associated with hypertension
III. World Hypertension Day 2023
A. Background and significance of World Hypertension Day
B. Theme and key messages for World Hypertension Day 2023
C. Activities and events organized worldwide to raise awareness
IV. Goals and Objectives
A. Key goals set for World Hypertension Day 2023
B. Promoting prevention and early detection of hypertension
C. Encouraging healthy lifestyle modifications
D. Enhancing public knowledge about hypertension management
V. Initiatives and Campaigns
A. Overview of global initiatives and campaigns
B. Collaborations with international organizations, NGOs, and healthcare professionals
C. Campaign materials and resources available for public use
VI. Strategies for Hypertension Prevention and Control
A. Implementing population-level interventions
B. Screening and diagnosis strategies
C. Lifestyle modifications (diet, physical activity, stress management)
D. Pharmacological management and treatment guidelines
VII. Public Awareness and Education
A. Importance of raising public awareness about hypertension
B. Educational campaigns and resources for the general public
C. Role of healthcare professionals in educating patients
VIII. Impact and Achievements
A. Highlighting the impact of previous World Hypertension Day campaigns
B. Success stories and achievements in hypertension prevention and control
C. Lessons learned and areas for improvement
IX. Conclusion
A. Recap of the key points discussed
B. Call to action for individuals, communities, and policymakers
C. Encouragement to spread awareness and take steps towards hypertension prevention
Dr. Sachin Verma is a young, diligent and dynamic physician. He did his graduation from IGMC Shimla and MD in Internal Medicine from GSVM Medical College Kanpur. Then he did his Fellowship in Intensive Care Medicine (FICM) from Apollo Hospital Delhi. He has done fellowship in infectious diseases by Infectious Disease Society of America (IDSA). He has also done FCCS course and is certified Advance Cardiac Life support (ACLS) and Basic Life Support (BLS) provider by American Heart Association. He has also done a course in Cardiology by American College of Cardiology and a course in Diabetology by International Diabetes Centre. He specializes in the management of Infections, Multiorgan Dysfunctions and Critically ill patients and has many publications and presentations in various national conferences under his belt. He is currently working in NABH Approved Ivy super-specialty Hospital Mohali as Consultant Intensivists and Physician.
All what you have to know about Diabetes MellitusYapa
All what you have to know about Diabetes Mellitus is here.Introduction of Diabetes,Regulation of blood glucose,Predisposing factors of DM,Clinical presentation,DM and pregnancy ,Diabetes ketoacidosis ,Complications of DM ,Diagnosis ,Dietary management of DM & Prevention of DM.
Student seminar on Diabetes Mellitus presented by 2007/2008 Batch students of Faculty of Medicine,University of Peradeniya,Sri Lanka.
Diabetes mellitus (DM) refers to a group of common metabolic disorders that share the phenotype of hyperglycemia.
Several distinct types of DM are caused by a complex interaction of genetics and environmental factors.
Depending on the etiology of the DM, factors contributing to hyperglycemia include reduced insulin secretion, decreased glucose utilization, and increased glucose production.
The metabolic dysregulation associated with DM causes secondary pathophysiologic changes in multiple organ systems that impose a tremendous burden on the individual with diabetes and on the health care system.
Represents 30% of all deaths worldwide (15 million deaths/year)
Leading cause of death and disability
CVD burden in developing countries
Risk factors worldwide
All what you have to know about Diabetes MellitusYapa
All what you have to know about Diabetes Mellitus is here.Introduction of Diabetes,Regulation of blood glucose,Predisposing factors of DM,Clinical presentation,DM and pregnancy ,Diabetes ketoacidosis ,Complications of DM ,Diagnosis ,Dietary management of DM & Prevention of DM.
Student seminar on Diabetes Mellitus presented by 2007/2008 Batch students of Faculty of Medicine,University of Peradeniya,Sri Lanka.
Diabetes mellitus (DM) refers to a group of common metabolic disorders that share the phenotype of hyperglycemia.
Several distinct types of DM are caused by a complex interaction of genetics and environmental factors.
Depending on the etiology of the DM, factors contributing to hyperglycemia include reduced insulin secretion, decreased glucose utilization, and increased glucose production.
The metabolic dysregulation associated with DM causes secondary pathophysiologic changes in multiple organ systems that impose a tremendous burden on the individual with diabetes and on the health care system.
Represents 30% of all deaths worldwide (15 million deaths/year)
Leading cause of death and disability
CVD burden in developing countries
Risk factors worldwide
HYPERTENSION- THE LATEST MANAGEMENT
Dr. Awadhesh kumar sharma is a young, diligent and dynamic interventional cardiologist. He did his graduation from GSVM Medical College Kanpur and MD in Internal Medicine from MLB Medical college jhansi. Then he did his superspecilisation degree DM in Cardiology from PGIMER & DR Ram Manoher Lohia Hospital Delhi. He had excellent academic record with Gold medal in MBBS,MD and first class in DM.He was also awarded chief ministers medal in 2009 for his academic excellence by former chief minister of UP Smt Mayawati in 2009.He is also receiver of GEMS international award.He had many national & international publications.He is also in editorial board of international journal- Journal of clinical medicine & research(JCMR).He is also active member of reviewer board of many journals.He is also trainee fellow of American college of cardiology. He is currently working in NABH Approved Gracian Superspeciality Hospital Mohali as Consultant Cardiologist.
2017 ACC AHA guidelines on management of systemic hypertensionVasif Mayan
the latest 2017 ACC/AHA guidelines on systemic Hypertension
latest cutoff for systemic hypertension : 130/80 mm Hg
american college of cardiology
american heart association
2017 guidelines
Webinar on Hypertension- The Silent Killer : Hinduja HospitalHinduja Hospital
Hypertension is a condition in which the force of blood against artery walls is high enough to cause health complications.
The more blood the heart pumps and the narrower the arteries, the higher the blood pressure.
Many a times, you can have hypertension for years without any symptoms. If the blood pressure is uncontrolled, it increases the risk of serious health problems, including heart attack and stroke.
Fortunately, hypertension can be easily detected. And if diagnosed, you can work with your doctor to control it.
To know more, read on Hypertension by our Consultant Internal Medicine, Dr. Anil Ballani.
This lecture presents the 1-Updated recommendations regarding definition and proper diagnosis of HTN. 2-Updated guidelines for threshold of BP to start treatment and targets of treatment. 3- Updated recommendations on CV risk assessment and management. 4-Hypertension and comorbidities: updated guidelines
#flozins
🫀DAPA 🆚placebo in HFpEF
Now we have a positive trial!
⬇️18% in CV☠️ death or
worsening HF among LVEF>40%
⬇️ 21%heart failure
💥Results same for LVEF> 60% 🆚LVEF<60%
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
1. HTN
The Silent Killer
ADA 2013 guidelines
STEMI 2013 guidelines
BHS 2011 guidelines
Dr Ihab Suliman
25/3/2013
2. Leading risks for
premature death
HYPERTENSION 1
Tobacco Use 2
Alcohol 3
Cholesterol 4
Overweight 5
(World Health Organization 2002)
3. HTN: KEY CONTRIBUTOR TO DIABETES
COMPLICATIONS
Framingham Study: DM ⊕ HTN vs DM alone
Relative Risk
of
Complication
Total mortality ↑ 72%
CVD events ↑ 57%
• HTN → 44% of deaths and 41% of CVD events in DM!
‒ ↑ risk of nephropathy/retinopathy/neuropathy 60-100%
Hypertension 2011; 57:891 Lancet 2012; 380:601
4. HTN PREVALENCE: GENERAL vs DM
POPULATIONS
north american data UTAH
BP ≥ 140/90 BP ≥ 130/80
General population 30% ---
• Age ≥ 60y 67% ---
• White 29% ---
• Black 41% ---
• Hispanic 26% ---
---
Persons with DM 67% 76%
HTN is more than twice as common in DM!
JACC 2012; 60:599 Diabetes Care 2011; 34:1597 Am J Med 2009; 122:443
Utah State Health Department, 2012
5. Background
• Each 2 mmHg rise in systolic blood pressure
associated with increased risk of mortality:
– 7% from heart disease
– 10% from stroke.
6. Properly Measured
Cuff Size
Bilateral
Confirm with Manual
No recent caffeine or Smoking
7. How many BP readings?
1. 3 – in sinus
rhythm
2. more if there
are multiple
ectopics or AF
8. Definitions
Stage 1 hypertension:
CBP >140/90 and ABPM or HBPM
>135/85 mmHg
Stage 2 hypertension:
CBP >160/100 and ABPM or HBPM daytime
>150/95 mmHg
Severe hypertension:
C SBP >180 or C DBP >110 mmHg
9. Diagnosis
If C.B.P. >140/90 mmHg, offer ABPM to confirm the
diagnosis
ABPM:
–at least two measurements per hour, at least 14
measurements
HBPM:
–two consecutive seated measurements, at least 1 minute
apart
–BP twice a day for at least 4 days
–measurements on the first day are discarded
10. Monitoring drug treatment
Use C.B.P. measurements to monitor response to
treatment. Aim for target
<140/90 mmHg in people <80y
<150/90 mmHg in people aged >80y
For people with ‘white-coat effect’* consider ABPM or
HBPM as an adjunct to C.B.P. to monitor response to
treatment.
Aim for ABPM/HBPM target
<135/85 mmHg in people <80y
<145/85 mmHg in people >80y
*White-coat effect: a discrepancy of more than 20/10 mmHg
between clinic BP and average daytime ABP or average HBP at the
time of diagnosis.
11. HTN: DOMINANT CONTRIBUTOR TO GLOBAL
MORTALITY
Increases RR by 2.0-4.0 fold for:
• CAD, stroke, HF, PAD
• Renal failure, AF, dementia, ↓ cognition
Attributable risk for HTN:
• Stroke 62% • MI 25%
• CKD 56% • Premature death 24%
• HF 49%
Aftermath:
• Shortens lifespan 5y
• $93.5 billion/y in U.S.
Circulation 2012; 125:e12 J Hum Hypertension 2008; 22:63 Hypertension 2007; 50:1006
12. Definitions from BHS 2011
Stage 1 hypertension:
• Clinic blood pressure (BP) is 140/90 mmHg or
higher and
• ABPM or HBPM average is 135/85 mmHg or
higher.
Stage 2 hypertension:
• Clinic BP 160/100 mmHg is or higher and
• ABPM or HBPM daytime average is
150/95 mmHg
or higher.
13. Monitoring drug treatment (1)
Use clinic blood pressure measurements to monitor
response to treatment. Aim for target blood pressure
below:
140/90 mmHg in people aged under 80
150/90 mmHg in people aged 80 and over
14. Choosing drugs for patients newly diagnosed
with hypertension
BHS Guidelines (2011)
55 years or older
Younger than 55 years Or black patients
Abbreviations: of any age
A: ACE-I (or
ARB if ACE A C Step 1
intolerant)
C: CCB
A+C Step 2
D: thiazide
type diuretic
A+C+D Step 3
Add
•further diuretic therapy
•Or alpha blocker Step 4
•Or Beta Blocker
•Consider seeking specialist advice
15. CCBs - Pharmacokinetics
High oral absorption, but high first pass metabolism (except
amlodipine) – individual variation and highly plasma protein bound
Extensively distributed in tissues and metabolized in liver and
excreted in urine, eliminated in 22-6 Hrs (except amlodipine)
Drug Bioavailability Vd (L/kg) Active Elim half life(hr)
% metabolite
Verapamil 15-30 5.0 Y 4-6
Diltiazem 40-60 3.0 Y 5-6
Nifedepine 30-60 0.8 M 2-5
Felodipine 15-25 10.0 None 12-18
Amlodipine 60-65 21.0 None
35-45
16. Case
55 years old obese Diabetic with Type 2 DM,
SBP is consistently above 150 mmHg, the best
initial treatment will be ???
1-HCTZ 12.5 mg po daily.
2-Atenolol 50 mg po daily.
3-Lisinopril 10 mg po daily
17. Lisinopril 10 mg po daily is chosen
You FU the patient by
A-POTASSIUM
B-RENIN
C-CREATININE
D-ECG
E— A&C
F-A,B,C,D
18. E— A&C
The patient after starting Lisinopril will be seen
after with Basic Screen
A- one week then 3 monthy
B- every 3 months
C- within 3 days then 3months
20. 45 years old male with DM , Prior history of
IHD, Last echo report EF 45%, SBP 155,
Creatinine 140, potassium 4, started on
lisinopril 10 mg po daily, after 3 month on a
routine visit SBP 115, creatinine 155, potassium
is 4.5 , No chest Pain or SOB, the next step will
be ????
22. 70 years old female with no prior active cardiac
problems, Informed in a private clinic about
being Hypertensive, 3 separate visits, SBP 160-
170 ,what is the next step??
A-life style modfication.
B-single agent anti hypertensive
C- combination of two anti hypertensive agents.
D- a diagnosis of HTN cannot be made at this
time.
23. C- combination of two anti hypertensive agents.
27. Recommendations: Hypertension/Blood Pressure
Control
Screening and diagnosis
Blood pressure should be measured at
every routine visit
Patients found to have elevated blood
pressure should have blood pressure
confirmed on a separate day (B)
ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S28-S29.
28. Recommendations: Hypertension/Blood Pressure
Control
Treatment (1)
Patients with a blood pressure (BP)
>120/80 mmHg should be advised on
lifestyle changes to reduce BP (B)
Patients with confirmed BP ≥140/80
mmHg should, in addition to lifestyle
therapy, have prompt initiation and timely
subsequent titration of pharmacological
therapy to achieve BP goals (B)
ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S29.
29. Recommendations: Hypertension/Blood Pressure
Control
Lifestyle therapy for elevated BP (B)
Weight loss ifoverweight
DASH-style dietary pattern including
reducing sodium, increasing potassium
intake
Moderation of alcohol intake
Increased physical activity
ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S29.
30. Recommendations: Hypertension/Blood
Pressure Control
Pharmacological therapy for patients with diabetes and
hypertension (C)
A regimen that includes either an ACE inhibitor or
angiotensin II receptor blocker; if one class is not tolerated,
substitute the other
Multiple drug therapy (two or more agents at maximal
doses) generally required to achieve BP targets (B)
Administer one or more antihypertensive medications
at bedtime (A)
ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S29.
31. Recommendations: Hypertension/Blood Pressure
Control
If ACE inhibitors, ARBs, or diuretics are used,
kidney function, serum potassium levels should be
monitored (E)
In pregnant patients with diabetes and chronic
hypertension, blood pressure target goals of 110–
129/65–79 mmHg are suggested in interest of
long-term maternal health and minimizing impaired
fetal growth; ACE inhibitors, ARBs, contraindicated
during pregnancy (E)
ADA. VI. Prevention, Management of Complications. Diabetes Care 2013;36(suppl 1):S29.
38. Anatomical Location of Renal
Sympathetic Nerves
• Arise from T10-L1
• Follow the renal artery to the kidney
• Primarily lie within the adventitia
39. Anatomical Location of Renal
Sympathetic Nerves
• Arise from T10-L1
• Follow the renal artery to the kidney
• Primarily lie within the adventitia
Vessel
Lumen
Media
Adventitia
Renal
Nerves
40. RF Ablation Approach to Renal
Sympathetic Denervation
Electrode
Insulated
arch wire
Symplicity® Catheter System,
Ardian, Inc., Palo Alto, CA, USA
Slide 6: The slide illustrates the importance of hypertension in relationship to other risks for premature death. The data is from a study of the World Health Organization that found that hypertension is the leading risk for death in women and the second leading risk for death in men in countries like Canada.
NOTES FOR PRESENTERS: Key points to raise: Hypertension is a major risk factor for ischaemic and haemorrhagic stroke, myocardial infarction, heart failure, chronic kidney disease, cognitive decline and premature death. Untreated hypertension is usually associated with a progressive rise in blood pressure. The vascular and renal damage that this may cause can culminate in a treatment-resistant state. Blood pressure is normally distributed in the population and there is no natural cut-off point above which 'hypertension' definitively exists and below which it does not. The risk associated with increasing blood pressure is continuous, with each 2 mmHg rise in systolic blood pressure associated with a 7% increased risk of mortality from ischaemic heart disease and a 10% increased risk of mortality from stroke. Routine periodic screening for high blood pressure is now commonplace in the UK as part of National Service Frameworks for cardiovascular disease prevention. Consequently, the diagnosis, treatment and follow-up of people with hypertension is one of the most common interventions in primary care, accounting for approximately 12% of Primary Care consultation episodes and approximately £1billion in drug costs in 2006.
NOTES FOR PRESENTERS: Definitions In this guideline the following definitions are used: Stage 1 hypertension Clinic blood pressure is 140/90 mmHg or higher and subsequent ambulatory blood pressure monitoring (ABPM) daytime average or home blood pressure monitoring (HBPM) average blood pressure is 135/85 mmHg or higher. Stage 2 hypertension Clinic blood pressure is 160/100 mmHg or higher and subsequent ABPM daytime average or HBPM average blood pressure is 150/95 mmHg or higher. Severe hypertension Clinic systolic blood pressure is 180 mmHg or higher or clinic diastolic blood pressure is 110 mmHg or higher. Additional information: ABPM – ambulatory blood pressure monitoring HBPM – home blood pressure monitoring
NOTES FOR PRESENTERS: These recommendations are not key priorities but have been included as they direct the management of hypertension. Recommendations in full: Use clinic blood pressure measurements to monitor the response to antihypertensive treatment with lifestyle modifications or drugs. [new 2011] [1.5.4] Aim for a target clinic blood pressure below 140/90 mmHg in people aged under 80 years with treated hypertension. [new 2011] [1.5.5] Aim for a target clinic blood pressure below 150/90 mmHg in people aged 80 years and over, with treated hypertension. [new 2011] [1.5.6]
“ Standards of Medical Care in Diabetes—2013” comprises all of the current and key clinical recommendations of the American Diabetes Association (ADA) These standards of care are intended to provide clinicians, patients, researchers, payers, and other interested individuals with the components of diabetes care, general treatment goals, and tools to evaluate the quality of care While individual preferences, comorbidities, and other patient factors may require modification of goals, targets that are desirable for most patients with diabetes are provided; specifically titled sections of the standards address children with diabetes, pregnant women, and people with prediabetes These standards are not intended to preclude clinical judgment or more extensive evaluation and management of the patient by other specialists as needed; for more detailed information about management of diabetes, refer to references The recommendations included are screening, diagnostic, and therapeutic actions that are known or believed to affect health outcomes of patients with diabetes favorably; a large number of these interventions have been shown to be cost-effective The slides are organized to correspond with sections within the “Standards of Medical Care in Diabetes—2013” While not every section in the document is represented, these slides do incorporate the most salient points from the Position Statement These standards of care are revised annually by the ADA’s multidisciplinary Professional Practice Committee, incorporating new evidence; subsequently, they are reviewed and approved by the Executive Committee of ADA’s Board of Directors Reference American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care 2013;36(suppl 1):S11.
Hypertension is a common comorbidity of diabetes that affects the majority of patients, with prevalence depending on type of diabetes, age, obesity, and ethnicity Hypertension is a major risk factor for both CVD and microvascular complications In type 1 diabetes, hypertension is often the result of underlying nephropathy, while in type 2 diabetes it usually coexists with other cardiometabolic risk factors This slide and the following five slides summarize recommendations for screening and diagnosis, goals, and treatment for hypertension/blood pressure control in patients with diabetes Slide 1 of 6 – Screening and Diagnosis Blood pressure should be measured at every routine visit Patients found to have elevated blood pressure should have blood pressure confirmed on a separate day (B) Reference American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care 2013;36(suppl 1):S28-S29.
This set of six slides summarize recommendations for screening and diagnosis, goals, and treatment for hypertension/blood pressure control in patients with diabetes Slide 3 of 6 – Treatment (Slide 1 of 4) Patients with a blood pressure >120/80 mmHg should be advised on lifestyle changes to reduce blood pressure (B) Patients with confirmed blood pressure ≥140/80 mmHg should, in addition to lifestyle therapy, have prompt initiation and timely subsequent titration of pharmacological therapy to achieve blood pressure goals (B) Reference American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care 2013;36(suppl 1):S29.
This set of six slides summarize recommendations for screening and diagnosis, goals, and treatment for hypertension/blood pressure control in patients with diabetes Slide 4 of 6 – Treatment (Slide 2 of 4) Lifestyle therapy for elevated blood pressure consists of weight loss if overweight, DASH-style dietary pattern including reducing sodium and increasing potassium intake, moderation of alcohol intake, and increased physical activity (B) Reference American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care 2013;36(suppl 1):S29.
This set of six slides summarize recommendations for screening and diagnosis, goals, and treatment for hypertension/blood pressure control in patients with diabetes Slide 5 of 6 – Treatment (Slide 3 of 4) Pharmacologic therapy for patients with diabetes and hypertension should be paired with a regimen that included either an ACE inhibitor or an angiotensin II receptor blocker (ARB); if one class is not tolerated, the other should be substituted Multiple drug therapy (two or more agents at maximal doses) is generally required to achieve blood pressure targets (B) Administer one or more antihypertensive medications at bedtime (A) Reference American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care 2013;36(suppl 1):S29.
This set of six slides summarize recommendations for screening and diagnosis, goals, and treatment for hypertension/blood pressure control in patients with diabetes Slide 6 of 6 – Treatment (Slide 4 of 4) If ACE inhibitors, angiotensin II receptor blockers (ARBs), or diuretics are used, serum creatine/estimated glomerular filtration rate (eGFR) and serum potassium levels should be monitored (E) In pregnant women with diabetes and chronic hypertension, blood pressure target goals of 110-129/65-79 mmHg are suggested in the interest of long-term maternal health and minimizing impaired fetal growth ACE inhibitors and angiotensin II receptor blockers (ARBs) are contraindicated during pregnancy (E) Reference American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care 2013;36(suppl 1):S29.